Bioreactor - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The bioreactor market size is estimated at USD 6.09 billion in 2026, and is expected to reach USD 8.58 billion by 2031, at a CAGR of 7.10% during the forecast period (2026-2031). This report is Segmented by Type (Glass, and More), Usage (Lab-Scale, Pilot-Scale, and Full-Scale), Scale (5L-20L, 20L-200L, 200L-1, 500L, and Above 1, 500L), Control Type (Manual and Automated), Bioprocess (Batch, and More), Application (Pharmaceutical & Biopharmaceutical, and More), End User (Biopharma, and More), and Geography (North America, Europe, and More). Market Forecasts are Provided in Value (USD).

Global Bioreactor Market Trends and Insights

Expanding Cell & Gene Therapy Manufacturing Pipelines

Distributed manufacturing models for autologous CAR-T and allogeneic therapies favor smaller-footprint equipment over centralized mega plants. AGC Biologics has earmarked USD 350 million for a Yokohama site featuring 2,000-liter single-use vessels, while its Copenhagen campus doubled capacity with 16 similar units scheduled for 2026 start-up. Fujifilm Diosynth Biotechnologies is investing USD 1.2 billion in a North Carolina expansion that will utilize 20,000-liter reactors for viral-vector and mRNA programs. AstraZeneca opened a USD 300 million facility in Maryland in 2025 to co-locate clinical and commercial cell therapy production, thereby accelerating technology transfer cycles. These moves show a shift toward owning strategic capacity to protect intellectual property and margins, increasing competition for bioprocess engineers and single-use consumables. As a result, the bioreactor market is moving toward modular, rapidly deployable suites that can be replicated across global sites without extensive civil construction.

Growing Adoption of Single-Use Bioreactor Technology

Single-use platforms have surpassed pilot adoption and now dominate early-stage commercial production. Thermo Fisher Scientific released the HyPerforma DynaDrive 2.0 in 2025, reducing shear stress by 25% and enabling perfusion at cell densities exceeding 100 million cells/mL. Sartorius followed with Biostat STR Generation 3, integrating optical DO sensors and automated pH control that removes four hours of manual calibration per batch. Scale ceilings continue to rise: AGC Biologics plans 5,000-liter single-use runs, pushing the boundaries once thought feasible only in stainless steel. While life-cycle assessments reveal that reusable systems generate three to five times less plastic waste than single-use systems, vendors such as Cytiva and Sartorius have launched take-back programs to recycle spent film and tubing for non-GMP applications. This dynamic keeps sustainability in focus without slowing the momentum of the bioreactor market as it heads into 2026.

Supply Chain Volatility for Medical-Grade Plastic Polymers

Spikes of 40%-60% in polyethylene and ethylene-vinyl-acetate resin pricing during 2021-2023 stabilized in 2024 but remain 25% above pre-pandemic levels, squeezing margins on single-use assemblies. Lead times for customized consumables increased from 12 weeks in 2019 to 26 weeks in 2024, forcing CDMOs to carry six months of safety stock, which ties up working capital. The EU’s Single-Use Plastics Directive exempts medical devices yet still pressures bioprocess suppliers to establish recycling schemes; Cytiva launched a European take-back program in 2025 to collect spent bags for mechanical recovery. Smaller manufacturers lack negotiating leverage with resin suppliers, creating a bifurcated market where top CDMOs secure favorable terms. At the same time, mid-tier players delay capacity plans, dampening bioreactor market growth in the short term.

Other drivers and restraints analyzed in the detailed report include:

• Government Funding for Pandemic Vaccine Capacity
• Rising Demand for Microbial Fermentation in Alternative Proteins
• High Capital Expenditure for Large-Scale Stainless-Steel Facilities

Geography Analysis

North America accounted for 43.00% of 2025 revenue, underpinned by Project NextGen’s USD 5 billion funding and a high concentration of CDMOs. Thermo Fisher’s USD 660 million Massachusetts expansion and Lonza’s USD 1 billion New Hampshire project exemplify the region’s commitment to both stainless-steel and single-use throughput. Canada’s USD 1.6 billion Life Sciences Strategy reduced cross-border dependency by funding 1,500-liter hybrid lines in Toronto and Montreal. While deep talent pools in Boston and San Francisco sustain innovation, high labor costs and lengthy permitting cycles encourage some companies to expand to friendlier jurisdictions overseas.

The Asia-Pacific region is the fastest-growing geography, with an 8.30% CAGR through 2031. Samsung Biologics’ USD 2.3 billion Bio Campus 4 delivers 256,000 liters in South Korea, positioning the country as a biosimilar powerhouse targeting EU and U.S. markets. WuXi Biologics chose Singapore for a USD 1.8 billion site combining mammalian and microbial fermentation, reflecting the city-state’s aggressive incentives. AGC Biologics’ USD 350 million Yokohama project focuses on domestic cell-therapy capacity, while India’s Biocon and Dr. Reddy’s target large-scale antibody work despite regulatory headwinds.

Europe remains a stalwart despite complex rules. Germany, Switzerland, and Ireland secured USD 3 billion in commitments for 2024-2025. Boehringer Ingelheim allocates EUR 500 million for four 15,000-liter reactors in Biberach. Thermo Fisher’s EUR 780 million Cork plant will manufacture single-use components and feature a cell-therapy suite, supported by Ireland’s favorable tax regime. The United Kingdom’s GBP 520 million agreement with Moderna for mRNA supply underscores the government's willingness to underwrite capacity. Elsewhere, Saudi Arabia and Brazil plan smaller projects under national-self-sufficiency strategies, hinting at future contributions to the bioreactor market after 2027.

List of Companies Covered in this Report:

• ABEC
• Applikon Biotechnology
• Bioengineering
• Bionet Innovative Technologies
• Cellexus International Ltd.
• Danaher
• Distek Inc.
• Eppendorf
• Esco Lifesciences
• GE Healthcare (Cytiva)
• Getinge
• Infors HT
• Kuhner Shaker AG
• Merck
• Pall
• PBS Biotech Inc.
• Pierre Guérin Technologies
• Sartorius
• Solaris Biotech
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support